ABIOMED to Present at Adams Harkness' 25th Annual Summer Seminar
DANVERS, Mass., July 25 /PRNewswire-FirstCall/ -- ABIOMED, Inc. (NASDAQ:ABMD)
announced today that Michael R. Minogue, Chairman, President and Chief
Executive Officer, will present at the Adams Harkness' 25th Annual Summer
Seminar on August 2, 2005 at 3:00 p.m. ET. The seminar will be held at the
Marriott Long Wharf Hotel in Boston.
A live webcast of the presentation will be made available on the Investor
Relations section of the ABIOMED website http://www.abiomed.com/. The webcast
will be archived for two weeks.
For more information about the Adams Harkness' 25th Annual Summer Seminar
please visit http://www.adamsharkness.com/.
ABOUT ABIOMED Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a
leading developer, manufacturer and marketer of medical products designed to
assist or replace the pumping function of the failing heart. ABIOMED currently
manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R)
5000 Biventricular Support System for the temporary support of all patients with
failing but potentially recoverable hearts. In Europe, ABIOMED offers the
Impella(R) Recover(TM) minimally invasive cardiovascular support systems under
CE Mark approval. The Company's AbioCor(R) Implantable Replacement Heart was
the subject of an initial clinical trial under an Investigational Device
Exemption from the United States Food and Drug Administration. The AbioCor has
not been approved for commercial distribution, and is not available for use or
sale outside of the initial clinical trial. For additional information please
visit: http://www.abiomed.com/.
Contacts:
Liza Heapes Investor Relations Contact:
ABIOMED, INC. Rx Communications Group, LLC
Communications Specialist Melody A. Carey
978-646-1668 917-322-2571
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements
regarding development of ABIOMED's existing and new products, the Company's
progress toward commercial growth, and future opportunities. The Company's
actual results may differ materially from those anticipated in these forward-
looking statements based upon a number of factors, including uncertainties
associated with development, testing and related regulatory approvals,
anticipated future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of additional
financing and other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the Annual Report filed on
Form 10-K. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this Release or to reflect
the occurrence of unanticipated events. DATASOURCE: ABIOMED, Inc.
CONTACT: Liza Heapes, Communications Specialist of ABIOMED, INC., +1-978- 646-1668, ; or Melody A. Carey, Investor Relations Contact of Rx Communications Group, LLC, +1-917-322-2571, Web site: http://www.abiomed.com/ http://www.adamsharkness.com/
|